Georgi Kamburov

Nutra Pharma Corp. (OTCMKTS:NPHC) Makes A Last-minute Surge

by Georgi Kamburov September 4, 2013
NPHCchart.pngAt the beginning of last week the stock of Nutra Pharma Corp. (OTCMKTS:NPHC, NPHC message board) made a sudden run up the chart when it more than doubled in price in just two sessions. On Tuesday the record number of 34 million traded shares boosted the ticker to a $0.022 close, just a little less than its high of day. Shareholders of the company had little time to rejoice though when on the very next day it crashed right back down on almost the same volume - 31 million shares.

The first session of this week once again saw them flying high but the jump in price does seem rather suspicious. For the majority of the day the price was fluctuating around $0.019 when less than an hour before closing time it shot up to $0.023. Most of the volume was also generated at the same time. Such a positive movement occurred without any new official announcements or new filings from the company so it may be hard for the momentum to spill over to today's session.

Despite describing themselves as a biotechnology company that is developing treatments for Multiple Sclerosis, HIV and Adrenomyeloneuropathy (AMN) their only available product is Nyloxin, an over-the-counter pain reliever made from Asian cobra venom. On July 24 they announced another pain relieving product but this time around aimed at pets and companion animals. In the following months we will see what the consumers' reaction towards it is going to be. 

Normally having a completed product that is capable of generating revenues would put any company ahead of its pennystock competition but NPHC has some rather discouraging fundamentals. For the quarter ending June 30 they disclosed :

  • ZERO cash
  • $153 thousand total assets
  • $3.8 million total liabilities
  • $ 22 thousand net sales
  • $600 thousand net loss

The only improvement compared to the same period last year was an increase in revenues from $16 thousand to $22 1PSONchart.pngthousand. This however hardly compensates for the five-times bigger costs of sale and net loss as a whole. They are still predominantly relying on loans from the CEO in order to fund their operations. For now most of the issued common stocks are restricted and the company is staying away from any involvement with paid pumpers.

After the long weekend the stock of InVivo Therapeutics Holdings Corp. (OTCBB:NVIV) received a nice 18% gain and closed at $1.41 while Petrosonic Energy, Inc. (OTCMKTS:PSON) continued its slide downards by another 21% to arrive at $0.39.

Comments 1

1. Guest
September 04, 2013, 07:17PM

Quotes Hi,
I have been interested in your program,but I stumbled across
an article where it is said that you/and/or your company had been hired as a promoter previously this would very much contradict your companies
principle
Also I am a bit confused I had this trial version of yours and I was going to delete it and it came up that I could purchase the very program for $ 9.00 rather then $ 49.00 ??
We do like the lay out of your program but with all the things going on out there and bad reviews we would like to hear your point on those matters.
Thanks in advance
Helga Schmidt
Please reply to helga.schmidt@bellaliant.net

Type the characters that you see in the box (5 characters).